Ultragenyx Pharmaceutical retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $-3.690B, a 18.85% increase year-over-year.
Ultragenyx Pharmaceutical retained earnings (accumulated deficit) for 2023 were $-3.388B, a 21.81% increase from 2022.
Ultragenyx Pharmaceutical retained earnings (accumulated deficit) for 2022 were $-2.781B, a 34.12% increase from 2021.
Ultragenyx Pharmaceutical retained earnings (accumulated deficit) for 2021 were $-2.074B, a 28.03% increase from 2020.